KPC Pharmaceuticals (SHA:600422) subsidiary Kunming Baker Norton Pharmaceutical secured the drug marketing authorization of its mycophenolate mofetil dry suspension from China's medical products administrator.
Mycophenolate mofetil is used to treat refractory rejection after a kidney transplant; inhibit rejection in kidney, heart, liver, lung, and pancreas transplants; as well as to treat lupus nephritis, according to a Wednesday filing with the Shanghai bourse.
Shares of the pharmaceutical company slid 2% in recent trade.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。